KCTBASE

알츠하이머병 치매 환자에서 도네페질(Donepezil)에 대한 최초 투약군과 전환군 간의 임상적 효용 비교 평가
Comparative Assessment of Clinical Efficacy between the Naive and the Switching Group to Donepezil：12 Months Prospective Study

노인정신의학 2010년 14권 2호 p.111 ~ p.117

강효신(Kang Hyo-Shin) - 삼성서울병원 삼성생명과학연구소 임상의학센터
안인숙(Ahn Inn-Sook) - 삼성서울병원 삼성생명과학연구소 임상의학센터
윤지혜(Yun Ji-Hae) - 삼성서울병원 삼성생명과학연구소 임상의학센터
문유진(Mooon Yu-Jin) - 삼성서울병원 삼성생명과학연구소 임상의학센터
황태영(Hwang Tae-Young) - 성균관대학교 의과대학 삼성서울병원 정신과학교실
이영민(Lee Young-Min) - 성균관대학교 의과대학 삼성서울병원 정신과학교실
김혜란(Kim Hye-Ran) - 성균관대학교 의과대학 삼성서울병원 정신과학교실
정재원(Chung Jae-Won) - 성균관대학교 의과대학 삼성서울병원 정신과학교실
김도관(Kim Doh-Kwan) - 삼성서울병원 삼성생명과학연구소 임상의학센터

Abstract

Objectives: The purpose of this study was to compare the efficacy between switching patients with Alzheimer’s disease (AD) from galantamine or rivastigmine to donepezil because they were not responding adequately, and naive patients with AD who initiated therapy with donepezil.

Methods: A total of 108 patients were recruited for this 52-week study. The effect of donepezil on cognitive function was measured using Alzheimer’s Disease Assessment Scale-cognitive subscale-preliminary Korean version (ADAS-cog-K). Patients’ activities of
daily living using Seoul-Activities of Daily Living (S-ADL) and the Seoul-Instrumental Activities of Daily Living (S-IADL)；behavioral symptoms using the Korean version Neuropsychiatric Inventory (K-NPI) were measured at baseline, 13-weeks, 26-weeks, 39- weeks and 52-weeks. We defined the responsive patients to donepezil at those who showed a cognitive improvement or no change during the first six-month clinical trial.

Results: 86 naive patients and 22 switching patients were enrolled in the study. 74 patients completed the study and 34 discontinued their treatment before week 52. There was no significant difference between two patient groups in demographic data, baseline
characteristics and dementia severity except duration of illness. The total ADAS-cog-K scores were not significantly different from baseline after 52 weeks of treatment in both groups. Both groups demonstrated deterioration of S-ADL and S-IADL at 52 weeks. The NPI scores did not significantly change in both groups. Based on the operational criteria, 61.6% of the naive group and 54.5% of the
switching group were responders to donepezil.

Conclusion: The switching group had similar levels of efficacy with the naive group who initiated therapy with donepezil. These results suggest that patients not responding adequately to rivastigmine or galantamine may improve or stabilize after switching to
donepezil and prior medication does not effect donepezil’s efficacy.

키워드

Alzheimer’s disease·Donepezil·Naive group·Switching group.

KMID : 0869220100140020111

원문 및 링크아웃 정보

등재저널 정보

주제코드

주제명(Target field)

연구대상(Population)

연구참여(Sample size)

대상성별(Gender)

질병특성(Condition Category)

연구환경(Setting)

연구설계(Study Design)

연구기간(Period)

중재방법(Intervention Type)

중재명칭(Intervention Name)

키워드(Keyword)

유효성결과(Recomendation)

Patients not responding adequately to rivastigmine or galantamine may improve or stabilize after switching to donepezil .

연구비지원(Fund Source)

근거수준평가(Evidence Hierarchy)

출판년도(Year)

참여저자수(Authors)

대표저자

DOI

KCD코드

ICD 03

건강보험코드

알츠하이머병 치매 환자에서 도네페질(Donepezil)에 대한 최초 투약군과 전환군 간의 임상적 효용 비교 평가 Comparative Assessment of Clinical Efficacy between the Naive and the Switching Group to Donepezil：12 Months Prospective Study

Abstract

키워드

알츠하이머병 치매 환자에서 도네페질(Donepezil)에 대한 최초 투약군과 전환군 간의 임상적 효용 비교 평가
Comparative Assessment of Clinical Efficacy between the Naive and the Switching Group to Donepezil：12 Months Prospective Study